<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709355</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-VM1500-08</org_study_id>
    <nct_id>NCT03709355</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs</brief_title>
  <official_title>Open-Label Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of ELPIDA® in Co-Administration With Other Drugs in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viriom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viriom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assesses PK and safety of other drugs, such as some antibiotics, proton pump
      inhibitors, statins, and combined oral contraceptives when co-administered with Elpida®
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the drug-drug interaction of Elpida® and other drugs (Rifampin,
      Rifabutin, Clarithromycin, Omeprazole, Atorvastatin and combinations of Levonorgestrel and
      Ethinylestradiol) according to changes in the PK parameters of the study substances in their
      single co-administration in healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of elsulfavirine</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of VM1500A</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of rifampicin</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of rifabutin</measure>
    <time_frame>49 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of clarithromycin</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of atorvastatin</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of levonorgestrel</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of ethinylestradiol</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of AEs and SAEs</measure>
    <time_frame>49 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Elpida®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Elpida® (capsule 20 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Rifampin (capsule 150 mg), Rifampin + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifabutin &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Rifabutin capsule 150 mg, Rifabutin + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Clarithromycin capsule 250 mg, Clarithromycin + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Omeprazole capsule 20 mg, Omeprazole + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Atorvastatin tablet 80 mg, Atorvastatin + Elpida® 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel+Ethinylestradiol &amp; Elpida®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Levonorgestrel 150 µg + Ethinylestradiol 150 µg tablet, Levonorgestrel + Ethinylestradiol + Elpida® 20mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elpida®</intervention_name>
    <description>Elpida® capsules, 20mg</description>
    <arm_group_label>Atorvastatin &amp; Elpida®</arm_group_label>
    <arm_group_label>Clarithromycin &amp; Elpida®</arm_group_label>
    <arm_group_label>Elpida®</arm_group_label>
    <arm_group_label>Levonorgestrel+Ethinylestradiol &amp; Elpida®</arm_group_label>
    <arm_group_label>Omeprazole &amp; Elpida®</arm_group_label>
    <arm_group_label>Rifabutin &amp; Elpida®</arm_group_label>
    <arm_group_label>Rifampin &amp; Elpida®</arm_group_label>
    <other_name>elsulfavirine</other_name>
    <other_name>VM1500</other_name>
    <other_name>VM-1500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampin capsules, 150mg</description>
    <arm_group_label>Rifampin &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>Rifabutin capsules, 150mg</description>
    <arm_group_label>Rifabutin &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Clarithromycin Film-coated tablets, 250mg</description>
    <arm_group_label>Clarithromycin &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole Film-coated tablets 20mg</description>
    <arm_group_label>Omeprazole &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin Film-coated tablets, 80mg</description>
    <arm_group_label>Atorvastatin &amp; Elpida®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel+Ethinylestradiol</intervention_name>
    <description>Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets</description>
    <arm_group_label>Levonorgestrel+Ethinylestradiol &amp; Elpida®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects must meet the following criteria to be enrolled in the study:

          1. Non-smoking men and women between the ages of 18 and 45 years (inclusive) (only women
             in Group 7);

          2. Verified &quot;healthy&quot; diagnosis according to standard clinical, laboratory and
             instrumental examination methods;

          3. Body Mass Index ranges between 18.5 kg/m2 and 30.0 kg/m2 and a body weight NLT 50 kg;

          4. Negative alcohol and drug tests;

          5. Consent to use two adequate and reliable methods of contraception throughout the study
             and up to 3 months after its completion: a condom with spermicide (foam, gel, cream,
             suppositories), or a diaphragm with spermicide, or a condom and diaphragm, or a condom
             and an intrauterine device;

          6. Signed Patient Information Sheet and form of Informed Consent to participate in the
             study.

        Exclusion Criteria:

        A subject will be considered not eligible to participate in the study if one or more of the
        following criteria is met:

          1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal
             system, as well as diseases of the gastrointestinal tract, liver, kidneys, blood;

          2. Variables of standard laboratory and instrumental parameters are beyond the normal
             limits (taking into account the acceptable limits of laboratory parameters;

          3. Surgical interventions on the gastrointestinal tract in medical history (except
             appendectomy);

          4. Systolic pressure below 90 mm Mercury or above 130 mm Mercury, diastolic pressure
             below 60 mm Mercury or above 85 mm Mercury, heart rate less than 60 BPM or more than
             90 BPM at screening;

          5. Regular intake of drugs less than 2 weeks prior to screening (including herbal
             preparations and dietary supplements); intake of drugs that have a pronounced effect
             on hemodynamics, hepatic function, etc. (for example, barbiturates, omeprazole,
             cimetidine, etc.) less than 30 days prior to screening;

          6. Presence of antibodies to HIV and hepatitis C virus, presence of hepatitis В surface
             antigen, a positive syphilis test;

          7. An unstable sleep structure (e.g., night work, sleep disorders, insomnia, recent
             return from another time zone, etc.), extreme physical activity (e.g. weight lifting),
             a special diet (e.g. vegetarian, vegan);

          8. Signs of alcohol (intake of more than 10 units of alcohol per week) or drug addiction;
             alcohol or drugs consumption within 4 days prior to screening; cigarettes smoking 3
             months prior to screening; positive drug and/or alcohol test;

          9. Drug allergies in medical history (including drug intolerance, including
             hypersensitivity to any components of study drugs) as well as food allergy;

         10. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

         11. Individual intolerance to any components of study drugs;

         12. Blood/plasma donation (450 ml of blood or plasma and more) less than 2 months prior to
             screening;

         13. Treatment with a study drug in framework of other clinical trials within 1 month prior
             to screening (including follow-up visits);

         14. Acute infectious diseases less than 4 weeks prior to screening;

         15. Inhibitors or inducers of CYP3A4/5, drugs that cause QT prolongation within 30 days
             prior to StD administration;

         16. For women - positive result of pregnancy test or breastfeeding; Inability to read or
             write; unwillingness to understand and adhere to the study protocol procedures;
             non-compliance with the drugs intake regimen or execution of procedures, which as the
             Investigator believes may affect the study results or subject's safety and prevent the
             subject from further participation in the study; any other associated medical or
             serious psychological conditions making the subject not eligible to participate in the
             clinical study, restricting legality of obtaining the Informed Consent or affecting
             the subject's ability to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Smolyarchuk, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.M. Sechenov First Medical State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alla Andreeva, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Smolensk Region Clinical Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Yakubova, PhD</last_name>
    <phone>+7 (495) 995-49-44</phone>
    <email>ey@chemrar.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia Vostokova, PhD</last_name>
    <phone>+7 (495) 995-49-44</phone>
    <email>nv@ipharma.ru</email>
  </overall_contact_backup>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

